Brian Piekos, CFO of KalVista Pharmaceuticals ($KALV), made two open market sales of company shares in the past year, totaling $87,646. His latest sale occurred on February 23, 2026. With no purchases recorded, his sales rank 9,759th out of 11,678 insiders, well below the average of $8.6 million and 6 transactions per insider.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| April 16, 2026 | KalVista Pharmaceuticals, Inc. | $KALV | Piekos Brian | Chief Financial Officer | M | Restricted Stock Unit | 6250 | $0.00 | 93,750.0000 | 53,883,681 | 6.25% | 0.01% |
| April 17, 2026 | KalVista Pharmaceuticals, Inc. | $KALV | Piekos Brian | Chief Financial Officer | S | Common Stock | 1862 | $20.22 | 18,150.0000 | 53,883,681 | 9.30% | 0.00% |
| April 16, 2026 | KalVista Pharmaceuticals, Inc. | $KALV | Piekos Brian | Chief Financial Officer | M | Common Stock | 6250 | $0.00 | 20,012.0000 | 53,883,681 | 45.41% | 0.01% |
| Feb. 21, 2026 | KalVista Pharmaceuticals, Inc. | $KALV | Piekos Brian | Chief Financial Officer | M | Common Stock | 5000 | $0.00 | 15,529.0000 | 53,883,681 | 47.49% | 0.01% |
| Feb. 21, 2026 | KalVista Pharmaceuticals, Inc. | $KALV | Piekos Brian | Chief Financial Officer | M | Restricted Stock Unit | 5000 | $0.00 | 60,000.0000 | 53,883,681 | 7.69% | 0.01% |
| Feb. 23, 2026 | KalVista Pharmaceuticals, Inc. | $KALV | Piekos Brian | Chief Financial Officer | S | Common Stock | 1767 | $15.57 | 13,762.0000 | 53,883,681 | 11.38% | 0.00% |
| Jan. 16, 2026 | KalVista Pharmaceuticals, Inc. | $KALV | Piekos Brian | Chief Financial Officer | A | Restricted Stock Unit | 100000 | $0.00 | 100,000.0000 | 53,883,681 | 9999.99% | 0.19% |
| Nov. 24, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Piekos Brian | Chief Financial Officer | S | Common Stock | 4471 | $13.45 | 10,529.0000 | 53,883,681 | 29.81% | 0.01% |
| Nov. 21, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Piekos Brian | Chief Financial Officer | M | Restricted Stock Unit | 15000 | $0.00 | 65,000.0000 | 53,883,681 | 18.75% | 0.03% |
| Nov. 21, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Piekos Brian | Chief Financial Officer | M | Common Stock | 15000 | $0.00 | 15,000.0000 | 53,883,681 | 9999.99% | 0.03% |
| Feb. 21, 2025 | KalVista Pharmaceuticals, Inc. | $KALV | Piekos Brian | Chief Financial Officer | A | Restricted Stock Unit | 80000 | $0.00 | 80,000.0000 | 46,590,154 | 9999.99% | 0.17% |
| Sept. 9, 2024 | KalVista Pharmaceuticals, Inc. | $KALV | Piekos Brian | Chief Financial Officer | A | Employee Stock Option (right to buy) | 100000 | $0.00 | 100,000.0000 | 36,786,575 | 9999.99% | 0.27% |
| Feb. 1, 2024 | Elicio Therapeutics, Inc. | $ELTX | Piekos Brian | Chief Financial Officer | A | Stock Option (right to buy) | 43225 | $0.00 | 43,225.0000 | 0 | 9999.99% | 0.00% |
| June 1, 2023 | Elicio Therapeutics, Inc. | $ELTX | Piekos Brian | Chief Financial Officer | A | Stock Option (right to buy) | 75484 | $0.00 | 75,484.0000 | 0 | 9999.99% | 0.00% |